gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · FENCHealthcareBiotechnology

Fennec Pharmaceuticals Inc. Common Stock (FENC)

$10.35−3.27%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$10.70▲ 31.61% in range
Nov 3, 2025Low $5.77 · High $12.78Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Fennec Pharmaceuticals closed at $10.35 on Nov 4, down 3.27%, 19.0% below its 52-week closing high. Volume of 160.6K shares was 1.25× its 20-day average (close to normal).

Split-adjusted performance: +0.0% over one month, +44.2% over six months, +27.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $17.87M, up 85.2% from a year earlier, with a net margin of 11.0%.

Short interest was 487.5K shares at the Oct 15 settlement, down 5.0% from the prior report (2.2% of float, 3.8 days to cover).

Market cap$362.9M35.1M shares
Revenue · quarter$17.9M+85.2% YoY
Diluted EPS$0.05—
P/E · TTM—P/S 6.1×
Net margin11.0%Gross 96.0%
Dividend yieldNone
52-week range5.77 – 12.78−19.0% from high
Volume160.6K1.25× 20-day avg
Volatility · 60d45.2%Annualised
Short % of float2.2%3.8 days to cover
Net cash$41.2MCash $41.2M
Next earnings—Not scheduled
Split-adjusted performance
1W −4.8%1M 0.0%3M −4.5%6M +44.2%YTD +34.4%1Y +27.3%3Y +50.4%5Y +14.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum88
Revenue growth82
Net margin77
Value (low P/E)—
Size58

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short487.5K−5.0% vs prior
Days to cover3.8Settled Oct 15
% of float2.2%
Short vol. 10d36.8%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
FENCFennec Pharmaceuticals$10.35−3.27%+44.2%+85.2%11.0%—$362.9M
SRZNSurrozen$31.65+5.08%−7.3%+408.6%640.8%—$372.0MCompare
EIKNEikon Therapeutics$6.39+15.14%−35.9%———$346.1MCompare
CCCCC4 Therapeutics$3.12−2.80%+6.5%+2.8%−355.9%—$383.8MCompare
ZURAZura Bio Limited$4.02+0.75%−17.8%———$387.2MCompare
TECXTectonic Therapeutic$20.30+6.95%−30.0%———$396.9MCompare
XFORX4 Pharmaceuticals$3.24+2.21%−26.0%+346.3%−183.5%—$321.2MCompare
ALLOAllogene Therapeutics$1.19+6.25%−48.5%—−919.8%—$411.1MCompare
KYTXKyverna Therapeutics$5.160.00%−45.5%———$319.1MCompare

News about Fennec Pharmaceuticals

All news →

No recent articles focused on Fennec Pharmaceuticals.

Quick answers

What does Fennec Pharmaceuticals do?
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children.
What is FENC's market cap?
$362.95M, based on the Nov 4 close of $10.35.
Does Fennec Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of FENC is sold short?
487.5K shares, 2.2% of float, as of Oct 15, 2026.
What sector is FENC in?
Healthcare, in the Biotechnology industry.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

HQ: Research Triangle Park, NC35 employeesListed Jan 28, 2002fennecpharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology